<DOC>
	<DOCNO>NCT00705497</DOCNO>
	<brief_summary>Background : This prospective study design first evaluate toxicity radiofrequency ablation ( RFA ) patient recurrent pediatric solid tumor . Methods : From 2003 2006 , conduct phase I , IRB-approved study RFA recurrent solid tumor . A multidisciplinary cancer management team select appropriate candidate study . Imaging-guided RFA perform percutaneously . Response assess 3 month . Repeat RFA perform incompletely ablated new lesion .</brief_summary>
	<brief_title>Radiofrequency Ablation Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<criteria>General Any age Previously diagnose malignancy ( include aggressive fibromatosis ) originally acquire childhood ( &lt; 21 yearsofage ) Patients undergone previous RFA may enrol ( different disease site ) receive subsequent ablation ( disease site ) long eligibility criterion meet time reenrollment , second ablation study . The subject medically appropriate study determine consensus professional multidisciplinary tumor conference prior enrollment . This discussion document chart potential subject recruit study . Histopathological material available prior RF ablation except patient obvious tumor recurrence . No Pacemakers Automatic Implantable Cardioverter/Defibrillators ( AICDs ) No tissue burn anticipate implanted metal Normal renal function ( Creatinine &lt; 2mg/dL ) Absolute neutrophil count ( ANC ) &gt; 1000/cu.mm . No uncorrectable coagulopathy ( INR &gt; 1.5 , PTT PT &gt; 1.5 x upper limit normal ) No uncorrectable thrombocytopenia ( platelet count &lt; 50,000/mm3 ) Life expectancy 30 day RF ablation target liver , lung musculoskeletal system meet follow criterion : Hepatic lesion Intrahepatic metastasis amenable therapy Primary hepatic tumor RF ablation portion tumor lead primary tumor resection rather hepatic transplantation Single primary multiple tumor liver At least one 0.5 cm diameter Edge lesion contiguous main hepatic common biliary duct . Musculoskeletal lesion Local regional recurrence primary bone soft tissue tumor amenable resection radiotherapy Osseous , soft tissue lymph node metastases amenable resection radiotherapy . Head , neck , spine , extremity , chest wall , flank , abdominal wall , pelvic bone girdle lesion treatable protocol RFA target &lt; 50 % axial area weight bear bone unless reinforce internal fixation ( bone cement infusion ) nonambulatory patient . Lung lesions No supplemental oxygenation require . Metastatic solid tumor recur progressed primary thoracotomy thoracoscopic removal amenable radiotherapy , surgery chemotherapy In investigator 's opinion , supplemental oxygen likely require rest 30 day RF ablation . Tumor burden &lt; 20 % lung volume</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Radiofrequency tumor ablation</keyword>
	<keyword>RFA</keyword>
</DOC>